Entering text into the input field will update the search result below

Sorrento jumps 4.5% after licensing rapid COVID-19 test from Columbia

  • Sorrento Therapeutics (NASDAQ:SRNE) climbs 4.5% after signing a licensing pact with Columbia University for the rights to a rapid one-step diagnostic test that detects SARS-CoV-2 virus in as little as 30 minutes from a saliva sample.
  • The test developed by Columbia's team, to be marketed by Sorrento under the COVI-TRACE name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point-of-care, on-site, or potentially at-home testing.
  • Previously: Sorrento to acquire COVID-19 therapy developer (July 24)

Recommended For You

About SRNEQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRNEQ--
Sorrento Therapeutics, Inc.